3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Polycystic Ovary Syndrome
10
Insulin Resistance
7
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
5
Diabetes Mellitus, Type 2
4
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Leukemia, Myeloid, Chronic-Phase
2
Carotid Intimal Medial Thickness 1
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene
1
Sleep Apnea, Obstructive
1
Skin Neoplasms
1
Recurrence
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Metabolic Syndrome
1
Meningioma
1
Memory Disorders
1
Lung Neoplasms
1
Liposarcoma, Myxoid
1
Liposarcoma
1
Leukemia, Myeloid, Acute
1
Inflammation
1
Hyperinsulinism
1
Glucose Intolerance
1
Glioblastoma
1
Cognitive Dysfunction
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cyclophosphamide
115
Dexamethasone
70
fludarabine phosphate
57
Cytarabine
56
fludarabine
52
Rituximab
51
Peripheral Blood Stem Cell Transplantation
40
Etoposide
40
Gemcitabine
39
Lenalidomide
38
pembrolizumab
33
Radiotherapy
33
Busulfan
33
Filgrastim
32
Carboplatin
31
Methotrexate
30
Cyclosporine
29
Cisplatin
29
Bortezomib
29
Mycophenolic Acid
28
Melphalan
28
venetoclax
27
Paclitaxel
26
Whole-Body Irradiation
24
Antilymphocyte Serum
23
Temozolomide
22
Granulocyte Colony-Stimulating Factor
20
Calcium Dobesilate
20
Bevacizumab
20
Tacrolimus
19
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Recurrence
×
Pioglitazone
×
Clear all
NCT01010243
2012-05-30
MM03
University of Regensburg
Phase 1/2
Unknown
54 enrolled